There are currently 67 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and New York.
Natural Killer Cell (CYNK-001) Infusions in Adults With AML
NCT04310592
Recruiting
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +9 locations
Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
Register for Updates
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
NCT03561259
Recruiting
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma
Gender:
All
Ages:
1 year and above
Trial Updated:
02/15/2023
Locations: Stanford University, Palo Alto, California +20 locations
Conditions: Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Register for Updates
AIMS Cancer Outcomes Study
NCT04495790
Recruiting
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Gender:
All
Ages:
All
Trial Updated:
01/30/2023
Locations: AIMS Institute, Seattle, Washington
Conditions: Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor, Oncology
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
12/09/2022
Locations: GSK Investigational Site, Goodyear, Arizona +71 locations
Conditions: Neoplasms
Register for Updates
Biomarkers For Immune Checkpoint Inhibitors
NCT04204434
Recruiting
This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney cancer and bladder cancer. The laboratories of Dr. Jack Elias and Dr. Chun Geun Lee at Brown University are studying how immune checkpoint inhibitors work.Kintai Therapeutics is a biotech company in Camb... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2022
Locations: Rhode Island Hospital, Providence, Rhode Island +1 locations
Conditions: Advanced Cancer, Neoplasms
Register for Updates
Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients
NCT03757182
Recruiting
The purpose of this study is to examine the relationships between objectively measured physical activity and provider-assessed and patient-reported functional outcomes in patients with advanced cancer. Findings from this study will help us better understand how change in daily physical activity, as measured using the wearable activity monitor, is related to change in a patient's functional status and clinical condition.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/30/2022
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Cancer, Cancer, Metastatic, Neoplasms
Register for Updates
PEN-866 in Patients With Advanced Solid Malignancies
NCT03221400
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: Highlands Oncology Group, Springdale, Arkansas +15 locations
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Register for Updates